Progress in the systemic treatment of advanced soft-tissue sarcomas

S. H. Okuno, J. H. Edmonson

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current systemic treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the systemic treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.

Original languageEnglish (US)
Pages (from-to)34-39
Number of pages6
JournalCancer Control
Issue number1
StatePublished - 1998

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Progress in the systemic treatment of advanced soft-tissue sarcomas'. Together they form a unique fingerprint.

Cite this